Nektar Therapeutics (NASDAQ:NKTR) Q1 2025 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR) Q1 2025 Earnings Call Transcript May 8, 2025Nektar Therapeutics misses on earnings expectations.
Posts Tagged ‘NASDAQ:NKTR’
10 Stocks Wall Street Is Calling Bullish Amid Market Turmoil
The S&P 500 is down 8.6% in a month while the Nasdaq has lost nearly 13%.
Nektar Therapeutics (NASDAQ:NKTR) Q4 2024 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR) Q4 2024 Earnings Call Transcript March 12, 2025Nektar Therapeutics misses on earnings expectations.
12 Best Penny Stocks to Invest in According to the Media
On December 24, Global Advisors’ managing partner, Tom Lee, shared his thoughts on the potential of small and mid-cap stocks in 2025.
Nektar Therapeutics (NASDAQ:NKTR) Q3 2024 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics' Third Quarter 2024 Financial Results Conference Call.
Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Nektar Therapeutics First Quarter 2024 Financial Results Conference Call. [Operator Instructions].
Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript
Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.22 EPS, expectations were $-0.2.
Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics Third Quarter 2023 Financial Results Conference Call.
12 Best Penny Stocks to Buy Under $1
Investors are optimistic as we move into the third quarter earnings season.
Nektar Therapeutics (NASDAQ:NKTR) Q2 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics Second Quarter 2023 Financial Results Conference Call.
Nektar Therapeutics (NASDAQ:NKTR) Q1 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics First Quarter 2023 Financial Results Conference Call.
Analysts Are Downgrading These 10 Pharmaceutical Stocks
In this article, we present the 10 pharmaceutical stocks that are being downgraded by analysts.
Billionaire Stanley Druckenmiller Just Dumped These 10 Stocks
In this article, we look at why billionaire Stanley Druckenmiller just dumped 10 stocks from his portfolio.
5 Healthcare Stocks to Buy According to Lee Ainslie’s Maverick Capital
In this piece, we will take a look at the 5 healthcare stocks to buy according to Lee Ainslie's Maverick Capital. If you want to learn more about Mr.
Should I Buy Nektar Therapeutics (NKTR)?
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns.
Hedge Funds Are Buying Nektar Therapeutics (NKTR)
The Insider Monkey team has completed processing the quarterly 13F filings for the June quarter submitted by the hedge funds and other money managers included in our extensive...
5 Pharmaceutical Stocks to Buy Today According to Tiger Cub Billionaire Lee Ainslie
In this article, we will discuss 5 pharmaceutical stocks to buy today according to Tiger Cub Billionaire Lee Ainslie.
Were Hedge Funds Right About Nektar Therapeutics (NKTR)?
Is Nektar Therapeutics (NASDAQ:NKTR) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment...
Is NKTR A Good Stock To Buy Now According To Hedge Funds?
We at Insider Monkey have gone over 817 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio...
Hedge Funds Are Coming Back To Nektar Therapeutics (NKTR)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Did Hedge Funds Make The Right Call On Nektar Therapeutics (NKTR) ?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Hedge Funds Aren’t Impressed By Nektar Therapeutics (NKTR)
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the...
Hedge Funds Are Betting On Nektar Therapeutics (NKTR)
We hate to say this but, we told you so.
Is Nektar Therapeutics (NKTR) A Good Stock To Buy?
We can judge whether Nektar Therapeutics (NASDAQ:NKTR) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas...
Is Nektar Therapeutics (NKTR) Going To Burn These Hedge Funds ?
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th.
Hedge Fund and Insider Trading News: James Dondero, Eddie Lampert, Chris Rokos, ExodusPoint Capital, SkyBridge Capital, Nektar Therapeutics Inc. (NKTR), Oshkosh Corp (OSK), and More
James Dondero doesn’t back down. That’s what helped him build Highland Capital Management into a credit giant that at one point oversaw $40 billion.
Hedge Fund and Insider Trading News: D.E. Shaw, GMT Capital, Citadel Investment Group, Aerie Pharmaceuticals Inc (AERI), Becton Dickinson and Co (BDX), and More
An ongoing legal battle between the high-powered hedge fund D.E.
Is Nektar Therapeutics (NKTR) A Good Stock To Buy?
Hedge funds are not perfect. They have their bad picks just like everyone else.
Were Hedge Funds Right About Souring On Nektar Therapeutics (NKTR)?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing.
Nektar Therapeutics (NKTR): Are Hedge Funds Right About This Stock?
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio...
Three Biotech Investment Ideas from Cormorant Asset Management
The biotech industry is regaining ground it lost in 2016 at full speed.
Market Movers Today: Tetraphase Pharmaceuticals Inc (TTPH), Twilio Inc (TWLO), Genesco Inc. (GCO), Nektar Therapeutics (NKTR), and More
Tetraphase Pharmaceuticals Inc's Ignite3 trial evaluating the company's lead drug candidate eravacycline for treating complicated urinary tract infections, or cUTIs, failed to...
Nektar Therapeutics (NKTR): Here’s What Just Happened
Nektar Therapeutics (NASDAQ:NKTR) is one of the week’s biggest winners in biotech so far, with the company soaring during the Monday session on the release of a fresh round ...
Nektar, AMD, Esperion, and More: Here’s Why These Five Stocks Are Surging
Although the broader markets are relatively calm, five stocks, Nektar Therapeutics (NASDAQ:NKTR), Advanced Micro Devices, Inc.
Nektar Therapeutics (NKTR): Hedge Fund Sentiment Unchanged
The worries about the election and the ongoing uncertainty about the path of interest-rate increases have been keeping investors on the sidelines.
Cormorant Asset Management’s Bets on Alder Biopharmaceuticals Inc (ALDR) and Other Healthcare Stocks Show Strong Returns
Bihua Chen's Cormorant Asset Management is one of some 750 investors that we track and whose quarterly 13F filings we analyze to identify stocks that they are collectively bullish...
Insider Buying at 3 Companies Amid Historically Low Insider Buying, Plus Insider Selling at 2 Companies
According to research firm TrimTabs, the dollar volume of insider buying from early-October through the end of last week stood at about $110 million, representing the lowest monthly...
Ups And Downs In Biotech This Week: PTC Therapeutics, Inc. (PTCT), Puma Biotechnology Inc (PBYI) and Nektar Therapeutics (NKTR)
It’s been another busy start to the week in biotech, with a number of companies moving double digit percentage points on various fundamental releases.
Stocks Going Viral Today: Staples, Nektar Therapeutics, Sealed Air Corp, More
Stocks indexes have jumped higher today amid better-than-expected earnings from Netflix, Inc. (NASDAQ:NFLX) and Goldman Sachs Group Inc (NYSE:GS), and a rally in oil prices.
Hedge Funds Aren’t Crazy About Nektar Therapeutics (NKTR) Anymore
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy...
These Five Biotech Stocks Ranked Among This UK-based Fund’s Favorites
Cheyne Capital is one of the few non-U.S firms that we track in our database.
bluebird bio Inc (BLUE), Nektar Therapeutics (NKTR) Among Billionaire Stan Druckenmiller’s Top Small-Cap Picks
Stan Druckenmiller’s Duquesne Family Office LLC, previously Duquesne Capital, has filed its 13F for the reporting period of March 31.
Nektar Therapeutics (NKTR), Pfizer Inc. (PFE): What’s MannKind Corporation (MNKD) Really Worth?
This is close to the market cap that Bank of America's Steve Byrne thinks MannKind Corporation (NASDAQ:MNKD) is worth.
Nektar Therapeutics (NKTR): Insiders Aren’t Crazy About It But Hedge Funds Love It
Now, according to many of your peers, hedge funds are assumed to be useless, outdated investment vehicles of a forgotten age.
Acorda Therapeutics Inc (ACOR): Insiders Aren’t Crazy About It But Hedge Funds Love It
To many investors, hedge funds are assumed to be bloated, outdated investment tools of a forgotten age.
Hedge Funds Are Selling Sarepta Therapeutics Inc (SRPT)
If you were to ask many of your fellow readers, hedge funds are seen as overrated, old investment vehicles of a period lost to current times.
Nektar Therapeutics (NKTR): A Pain Management Play That You Should Explore
Nektar Therapeutics (NASDAQ:NKTR) announced data last week that could become a breakthrough in the largest healthcare market in the U.S.
Nektar Therapeutics (NKTR), Stemline Therapeutics Inc (STML): Humongous Health-Care Stocks This Week
While the market jittered this week over what the Federal Reserve will do next, some stocks didn't flinch.
Is Nektar Therapeutics (NKTR) Going to Burn These Hedge Funds?
Nektar Therapeutics (NASDAQ:NKTR) was in 8 hedge funds' portfolio at the end of March.
